Replies to post #199818 on Biotech Values

[DewDiligence]

MNTA continues to have strong liquidity:

https://www.sec.gov/Archives/edgar/data/1235010/000110465916118813/a16-6503_110q.htm#CONDENSEDCONSOLIDATEDBALANCESHEE_114413

The 3/31/16 pro forma cash balance was $388.2M; this consisted of: $345.8M of unrestricted cash and marketable securities; $21.7M of collaboration receivables from MYL relating to the companies’ FoB partnership; and $20.7M of restricted cash (mostly related to the Lovenox patent case).

For the remaining nine months of 2016, MNTA’s cash-usage guidance—excluding all revenue from NVS and BXLT, but taking into account R&D reimbursement from MYL—is $120-135M (i.e. $40-45M per quarter).